高级检索
龙清忠, 李伟, 黄佑山, 周军和, 付家荣, 杨光耀, 戴德芳, 刘运芝, 贺恒章. 湖南省肾综合征出血热Ⅰ型灭活疫苗效果免疫(感染)增强和免疫策略研究[J]. 中国公共卫生, 1999, 15(7): 589-591.
引用本文: 龙清忠, 李伟, 黄佑山, 周军和, 付家荣, 杨光耀, 戴德芳, 刘运芝, 贺恒章. 湖南省肾综合征出血热Ⅰ型灭活疫苗效果免疫(感染)增强和免疫策略研究[J]. 中国公共卫生, 1999, 15(7): 589-591.
Long Qingzhong, . Evaluation; on the Efficacy of Vaccines Against HFRS and Study of Antibody Dependent Immunization Enhancement and Immunological Strategy[J]. Chinese Journal of Public Health, 1999, 15(7): 589-591.
Citation: Long Qingzhong, . Evaluation; on the Efficacy of Vaccines Against HFRS and Study of Antibody Dependent Immunization Enhancement and Immunological Strategy[J]. Chinese Journal of Public Health, 1999, 15(7): 589-591.

湖南省肾综合征出血热Ⅰ型灭活疫苗效果免疫(感染)增强和免疫策略研究

Evaluation; on the Efficacy of Vaccines Against HFRS and Study of Antibody Dependent Immunization Enhancement and Immunological Strategy

  • 摘要: 采用IFAT法检测特异IgG荧光抗体,用MCPENT法检测中和抗体滴度,追踪流行病学防病效果。结果表明,该疫苗的安全性较好,总反应率为3.19%,中强反应1.82%,反应以局部一过性疼痛多见,无异常反应。疫苗3针全程免疫后2周?加强前?加强后2周?1年和2年,3年中和抗体阳转率分别为31.40%?9.33%?87.50%?53.85%?38.10%和35.00%。荧光抗体阳转率分别为84.91%?22.50%?85.00%?15.79%?10.20%和9.05%。疫苗的流行病学防病效果好,3针全程免疫后(1995.4)至今(1999.3)接种者无人发病,对照组发病8例,保护率为100.00%,观察到试区疫情较四周非试区低,疫苗复盖率达50%以上,似可有效控制疫情。发现有1例接种者在经过一个流行高峰期后荧光抗体较前呈4周以上增高,但无临床表现。未发现接种人群中有免疫(感染)增强问题。

     

    Abstract: The purpose of this report was to observe the safety,serological and epidemiological efficacy of Type I inactivated vaccines against HFRS that was purified from mouse brains and supplied by Institute of Biological products Lanzhou.Methods Immunoflures-cent antibody assay was used in testing specific IgG antibody and Mcro-CPE method was used in testing the titer of neutralizing antibody.There is cohort study for epidemiological efficacy.Results This vaccine was safe.The rate of genernal response was 3.19%,and the rate of medium and strong response was 1.82%.Two weeks after three doses of infection before reinforced two weeks one year and two years after reinforced The rates of seroconversion of neutralizing antibody were 31.14%.9.33%.87.50%.53.85%.35.80% and 30.10% respectively.The rates of seroconversion of immunofluorescent antibody were 84.91%,22.50%,85.00%,15.79%,9.52% and 10.00% respectively.This vaccine has good efficacy in prevention disease.After three doses of injection there were no patients in the immunized group and eight cases in the control group,so the protection rate was 100%.After the epidemic peak,the inoculated individuals didnt show any clinical symptom but increase of immunofluorescent antibody was four times more than before.Till now we haven t find any antibody dependent immunization enhancement phenomenon among the inoculated population.Chonclusion:The type I vaccine(supplied by Institute of Biolocal Products.Lanzou) was safe and epidmiologically effective.We also offered some suggestions on the immunological strategy.

     

/

返回文章
返回